← Open Payments lookup

DONALD AMMERMAN: Open Payments

NPI 1316032295 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$411,966 in 505 payments from 7 companies in 2025. Trend: 2023 $251,336 · 2024 $279,657 · 2025 $411,966

Speaker / faculty: $367,823Travel & lodging: $23,449Food & beverage: $10,774Consulting: $9,920
CompanyPaymentsAmount
Neurocrine BioSciences, Inc.150$133,065
ABBVIE INC.162$132,253
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)121$112,901
Vanda Pharmaceuticals Inc.57$33,524
E.R. Squibb & Sons, L.L.C.11$135
Teva Pharmaceuticals USA, Inc.3$66
Otsuka America Pharmaceutical, Inc.1$22

Products named: INGREZZA, VRAYLAR, CAPLYTA, FANAPT, COBENFY, UZEDY, AUSTEDO XR, REXULTI.

Industry payments across CT — which companies pay providers there.